NewLink Genetics Corp (NASDAQ:NLNK) shares hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $1.70 and last traded at $1.72, with a volume of 7057 shares trading hands. The stock had previously closed at $1.80.
NLNK has been the topic of a number of recent analyst reports. Bank of America dropped their price objective on NewLink Genetics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, November 2nd. Zacks Investment Research raised NewLink Genetics from a “hold” rating to a “strong-buy” rating and set a $2.50 price objective on the stock in a research note on Wednesday, November 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $4.75.
The stock has a market cap of $64.40 million, a P/E ratio of -0.75 and a beta of 1.41.
Institutional investors have recently modified their holdings of the stock. Quantitative Systematic Strategies LLC bought a new stake in NewLink Genetics in the 2nd quarter valued at about $133,000. Russell Investments Group Ltd. bought a new stake in NewLink Genetics in the 3rd quarter valued at about $219,000. Marshall Wace LLP bought a new stake in NewLink Genetics in the 3rd quarter valued at about $244,000. Pennsylvania Trust Co increased its position in NewLink Genetics by 35.8% in the 3rd quarter. Pennsylvania Trust Co now owns 112,719 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 29,719 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in NewLink Genetics by 432.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 286,338 shares of the biotechnology company’s stock valued at $684,000 after buying an additional 232,530 shares in the last quarter. 38.32% of the stock is owned by institutional investors and hedge funds.
NewLink Genetics Company Profile (NASDAQ:NLNK)
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.
See Also: What is a conference call?
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.